Outcomes in a Modern Cohort of Treated Patients with Multiple Sclerosis from Diagnosis Up to 15 Years

Overview

Journal Int J MS Care

Date 2020 Jul 2

PMID 32607072

Citations 1

Authors

Thomas F Scott

Troy Desai

Chris Hackett

Edward J Gettings

Teresa Hentosz

Wisam Elmalik

Carol J Schramke

Affiliations

Soon will be listed here.

Abstract

Background: Before disease-modifying therapies (DMTs) were available, the natural history of multiple sclerosis (MS) regarding attainment of accepted disability milestones was reported with fairly wide variance comparing outcomes across studies. The influence of DMTs on these outcomes is unknown. This study aimed to calculate attainment of disability milestones during the first 15 years after onset of DMT-treated relapsing forms of MS (RMS).

Methods: As a retrospective study, all available disability data (collected routinely) on all newly diagnosed patients with RMS seen and initially diagnosed in a single clinic between 1989 and 2006 were reviewed. Times from first symptoms and diagnosis until first treatment with DMTs were also reviewed. Time-to-event statistics were applied using disability milestones.

Results: Mean follow-up of 184 adult patients from symptom onset was 13.7 years. Of patients followed up for 15 years after onset, 16 of 86 (19%) reached an Expanded Disability Status Scale (EDSS) score of 6.0. Estimated median time to reach an EDSS score of 3.0 was 10.7 years and to reach an EDSS score of 4.0 was 18.1 years.

Conclusions: There were striking differences between the present results and older data sets and similar results to the few available modern data sets. This analysis of a modern treated RMS cohort provides outcomes data that may be compared favorably with the natural history of RMS.

Citing Articles

Long-Term Disability Outcomes in Relapsing-Remitting Multiple Sclerosis Patients: Impact of Clinical and Demographic Factors on Disease Progression.

Barcutean L, Maier S, Bajko Z, Stoian A, Mosora O, Sarmasan E J Clin Med. 2024; 13(6).

PMID: 38542037 PMC: 10971344. DOI: 10.3390/jcm13061813.

References

Polman C, Reingold S, Banwell B, Clanet M, Cohen J, Filippi M . Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2):292-302. PMC: 3084507. DOI: 10.1002/ana.22366. View

OConnor P, Comi G, Freedman M, Miller A, Kappos L, Bouchard J . Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study. Neurology. 2016; 86(10):920-30. PMC: 4782117. DOI: 10.1212/WNL.0000000000002441. View

Scott T, Hackett C, Quigley M, Schramke C . Relapsing multiple sclerosis patients treated with disease modifying therapy exhibit highly variable disease progression: a predictive model. Clin Neurol Neurosurg. 2014; 127:86-92. DOI: 10.1016/j.clineuro.2014.09.008. View

Hum S, Lapierre Y, Scott S, Duquette P, Mayo N . Trajectory of MS disease course for men and women over three eras. Mult Scler. 2016; 23(4):534-545. DOI: 10.1177/1352458516655478. View

Leray E, Yaouanq J, Le Page E, Coustans M, Laplaud D, Oger J . Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010; 133(Pt 7):1900-13. PMC: 2892936. DOI: 10.1093/brain/awq076. View

Roxburgh R, Seaman S, Masterman T, Hensiek A, Sawcer S, Vukusic S . Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology. 2005; 64(7):1144-51. DOI: 10.1212/01.WNL.0000156155.19270.F8. View

Tintore M, Rovira A, Rio J, Otero-Romero S, Arrambide G, Tur C . Defining high, medium and low impact prognostic factors for developing multiple sclerosis. Brain. 2015; 138(Pt 7):1863-74. DOI: 10.1093/brain/awv105. View

Trojano M, Pellegrini F, Fuiani A, Paolicelli D, Zipoli V, Zimatore G . New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol. 2007; 61(4):300-6. DOI: 10.1002/ana.21102. View

Scott T, Schramke C . Poor recovery after the first two attacks of multiple sclerosis is associated with poor outcome five years later. J Neurol Sci. 2010; 292(1-2):52-6. DOI: 10.1016/j.jns.2010.02.008. View

10.

Runmarker B, Andersen O . Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993; 116 ( Pt 1):117-34. DOI: 10.1093/brain/116.1.117. View

11.

Menon S, Shirani A, Zhao Y, Oger J, Traboulsee A, Freedman M . Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013; 84(11):1192-8. DOI: 10.1136/jnnp-2013-304951. View

12.

Novotna M, Paz Soldan M, Zeid N, Kale N, Tutuncu M, Crusan D . Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology. 2015; 85(8):722-9. PMC: 4553030. DOI: 10.1212/WNL.0000000000001856. View

13.

Kappos L, Edan G, Freedman M, Montalban X, Hartung H, Hemmer B . The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology. 2016; 87(10):978-87. PMC: 5027814. DOI: 10.1212/WNL.0000000000003078. View

14.

Goodin D, Reder A, Ebers G, Cutter G, Kremenchutzky M, Oger J . Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 2012; 78(17):1315-22. PMC: 3335454. DOI: 10.1212/WNL.0b013e3182535cf6. View

15.

Tremlett H, Paty D, Devonshire V . Disability progression in multiple sclerosis is slower than previously reported. Neurology. 2006; 66(2):172-7. DOI: 10.1212/01.wnl.0000194259.90286.fe. View

16.

Confavreux C, Vukusic S, Moreau T, Adeleine P . Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000; 343(20):1430-8. DOI: 10.1056/NEJM200011163432001. View

17.

Cree B, Gourraud P, Oksenberg J, Bevan C, Crabtree-Hartman E, Gelfand J . Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016; 80(4):499-510. PMC: 5105678. DOI: 10.1002/ana.24747. View

18.

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

19.

Weinshenker B, Bass B, Rice G, Noseworthy J, Carriere W, Baskerville J . The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 1989; 112 ( Pt 1):133-46. DOI: 10.1093/brain/112.1.133. View

20.

Rudick R, Lee J, Cutter G, Miller D, Bourdette D, Weinstock-Guttman B . Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol. 2010; 67(11):1329-35. DOI: 10.1001/archneurol.2010.150. View